Lexaria Bioscience Corp. (NASDAQ: LEXX) announced on April 29, 2026, that it has extended its Material Transfer Agreement (MTA) with a pharmaceutical company, referred to as PharmaCO, through December 31, 2026. The original agreement, entered into on August 30, 2024, was designed to evaluate Lexaria’s patented DehydraTECH drug delivery technology in a pre-clinical setting. The extension allows PharmaCO additional time to receive and review Lexaria’s 2026 research and development results related to GLP-1 drugs, a class of therapeutics used for diabetes and obesity.
The extended MTA keeps a temporary exclusive license active and in force, and it opens the door for strategic planning discussions with PharmaCO’s human clinical and business development teams. This development is significant because it signals continued interest from a pharmaceutical partner in Lexaria’s platform, which aims to improve oral drug delivery by increasing bio-absorption, reducing side effects, and enhancing delivery across the blood-brain barrier.
Over the past 12 months, Lexaria has advanced its GLP-1 development program with three studies: Human Study #7, Animal Study #1, and Animal Study #2. All are fully funded with existing corporate resources, and results are expected during the third and fourth quarters of 2026. These studies are designed to provide comprehensive evidence to support further collaboration and potential licensing of the DehydraTECH technology.
Lexaria’s DehydraTECH platform has repeatedly shown the ability to improve oral drug delivery. The company holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. The extension of the MTA underscores the potential value of Lexaria’s technology in the competitive GLP-1 market, which includes blockbuster drugs like Ozempic and Wegovy.
While the announcement is positive, Lexaria cautioned that forward-looking statements involve risks and uncertainties, including regulatory approvals, competition, and the ability to realize benefits from collaborations. The company noted that no statement has been evaluated by the Food and Drug Administration, and its products are not intended to diagnose, treat, cure, or prevent any disease.
The extension of the MTA through the end of 2026 provides Lexaria with a continued pathway to potentially license its technology to a major pharmaceutical player, which could be transformative for the company. Investors will be closely watching the upcoming study results, which will be critical for determining the next steps in this partnership.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Lexaria Extends Material Transfer Agreement with PharmaCO Through 2026 for GLP-1 Drug Delivery Technology Evaluation.